BNP/CALL/MODERNA/100/0.1/17.01.25 | Delayed Deutsche Boerse AG 02:20:45 2024-07-09 am EDT | ||
| 2.81 EUR | +1.44% |
|
| 1 month | -49.91% | ||
| 3 months | +24.22% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-09 | 2.81 | +1.44% |
| 24-07-08 | 2.77 | -4.48% |
| 24-07-05 | 2.9 | -0.68% |
| 24-07-04 | 2.92 | +6.96% |
| 24-07-03 | 2.73 | -3.19% |
Delayed Quote Deutsche Boerse AG
Last update July 09, 2024 at 02:20 am EDT
More quotesStatic data
| Product type | Warrant Plain-Vanilla |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
BNP Paribas
|
| WKN | PN7FA9 |
| ISIN | DE000PN7FA93 |
| Date issued | 2023-08-17 |
| Strike | 100 $ |
| Maturity | 2025-01-17 (193 Days) |
| Parity | 10 : 1 |
| Emission price | 2.39 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.07 € |
|---|---|
| Lowest since issue | 0.84 € |
| Spread | 0.01 € |
| Spread % | 0.35% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116.4
USD
Average target price
145.9
USD
Spread / Average Target
+25.25%
- Stock Market
- Warrants
- Warrant
